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Summary
Bioactive compounds can be used to selectively
modulate gene function. We utilized a chemical ge-
netic approach to dissect the mammalian pigmen-
tation pathway and identify protein regulators. We
screened a tagged library of 1170 small molecules in
a cell-based assay and discovered a class of pigment-
enhancing chemicals. From this class we charac-
terized the small molecule melanogenin. Using mela-
nogenin bound to an affinity matrix and amino acid
sequencing, we identified the mitochondrial protein,
prohibitin, as an intracellular binding target. Studies
employing siRNA demonstrate that prohibitin is re-
quired for melanogenin to exert its propigmentary ef-
fects and reveal an unsuspected functional role for
this protein in melanin induction. This represents
a mechanism by which propigmentary signals are
transduced and ultimately provides a potential target
for the treatment of pigmentary disorders.
Introduction
Chemical genetics is a large-scale method that facili-
tates the discovery and identification of novel proteins
and their function through the screening of small mole-
cules in cells [1, 2]. Conditional and temporal control of
protein function and expression may be achieved
through the use of small molecules, and selective mod-
ulation of individual functions of multifunctional pro-
teins may also be accomplished [1]. Importantly, small
molecules can be used to directly identify protein
targets in biological pathways through affinity purifica-
tion [1–4]. Such target identification may provide new
avenues for rational drug design and gene-specific
therapies [1–4].
Melanin plays an important role in protection of the
skin from the deleterious effects of UV radiation. The
highest incidence of skin cancer is found in individuals
with low levels of endogenous pigmentation [5]. Agents
that promote pigmentation hold the potential to reduce
the incidence of UV-induced skin damage and carcino-
genesis [5]. Additionally, the mammalian pigmentation
response is complex and remains incompletely under-*Correspondence: seth.orlow@med.nyu.edustood. A complete molecular understanding of the pig-
mentation pathway will facilitate the treatment of disor-
ders such as oculocutaneous albinism, vitiligo, and
melanoma. Studies from the mouse genome suggest
that >100 loci are involved in pigmentation, many of
which remain unidentified. Systematic, large-scale
screens hold promise in the identification of these loci;
such studies have not yet been attempted. Cell-based
chemical genetics has been successfully utilized in the
dissection of other fundamental cellular pathways such
as glucose signaling [6], myotube fission [7], mitosis [8],
and plant auxin signaling [9], yielding potentially thera-
peutic small molecules and protein targets. Here we
discuss our chemical genetic approach to pigmen-
tation.
Using this approach, we have characterized the
small-molecule probe melanogenin and identified a
specific intracellular target as the mitochondrial protein
prohibitin. Studies employing siRNA reveal a functional
role for prohibitin in the pigmentation response, repre-
senting what we believe to be a novel mechanism by
which melanogenic signals are transduced and provid-
ing a potential target for specific therapies.
Results
Screening of a Tagged Triazine Library for Inducers
of Pigmentation in Melanocytes Yields the Potent
Promoter Melanogenin
We constructed a 1170-member tagged triazine-based
chemical library (Figure 1A) using an orthogonal syn-
thetic approach [10] for both screening and subsequent
target identification. We screened this tagged trisubsti-
tuted triazine library for compounds that promoted
pigmentation in cultured melanocytes (Figure 1A).
Screening was performed in 24-well plates (Figure 1A)
followed by quantitative melanin assay. Vehicle-treated
melanocytes, as well as cells treated with the melanin
induction agent isobutylmethylxanthine (IBMX), served
as negative and positive controls, respectively. We
established a minimum increase in melanin formation
of 160% over untreated melanocytes as significant for
promoters. Using this criterion, we identified a class of
pigment-enhancing chemicals from the library, resyn-
thesized and rescreened these compounds, and estab-
lished a subclass of 23 confirmed promoters, of which
melanogenin is a representative member (Figure 1A). All
confirmed active chemicals were noncytotoxic at con-
centrations below 20 M (data not shown). Melano-
genin was a potent inducer of pigmentation with an
EC50 of 2.5 M (data not shown).
To create an optimal negative control for future target
isolation experiments, we analyzed the initial screening
results in order to identify an inactive derivative of mel-
anogenin. We identified E28, a molecule that differs
structurally from melanogenin only at the R1 position
(Figure 1B) yet is inactive at multiple concentrations
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478Figure 1. A Chemical Genetic Approach to Pigmentation Yields Melanogenin, Believed to Be a Novel Small-Molecule Inducer of Melanogenesis
(A) In vitro screening of a 1170-member trisubstitued triazine library in cultured wild-type murine melanocytes.
(B) Chemical structures of melanogenin and an inactive derivative E28. Note that E28 differs structurally from melanogenin only at the
R1 position.
(C) Structure-activity relationship analysis of triazine library members. Structural variations were produced by chemically modifying the triazine
structure at the R1 and R2 positions. Chemical activity is expressed as the percent increase in pigmentation above untreated melanocytes.(data not shown). Resynthesis and rescreening alone t
tand in combination with melanogenin was performed
to ensure that E28 acted neither as a stimulator of pig- s
wmentation nor as an antagonist of melanogenin activity.
Multiple structural derivatives of melanogenin were t
ncreated by varying the functional groups at the R1 and
R2 positions (Figure 1C). Structure-activity relationship s
a(SAR) analysis of the confirmed promoters revealed
high activities correlating with electronegative fluori- p
pnated R1 and R2 groups, with the most significant in-
duction resulting from melanogenin, in which fluorina- (
stion exists at the meta position (Figure 1C).
2
sCharacterization of the Cellular Response
to Melanogenin w
tMelanogenin induced pigmentation and dendricity in
melanocytes (Figures 2A and 2B) and melanoma cells
(Figure 2F), which was a result not observed in cells I
Ptreated with DMSO vehicle. Melanogenin induced mel-
anin formation in a dose-dependent manner and was P
mmore potent than the known stimulator IBMX (Figure
2C). E28 was entirely inactive (Figure 2C). Western blot-ing revealed that melanogenin induced an upregula-
ion in levels (Figure 2D) and activity (Figure 2E) of tyro-
inase, the rate-limiting enzyme in melanogenesis,
hereas E28 had no significant effect (Figure 2D). Un-
reated melanocytes, as well as albino melan-C mela-
ocytes (expressing an inactive mutant tyrosinase) [12],
erved as controls in the tyrosinase activity assay. Mel-
nogenin had no effect on levels of a closely related
rotein involved in pigmentation, tyrosinase-related
rotein-1 (Trp-1), illustrating the specificity of its effect
Figure 2D). An additive pigmentary effect was ob-
erved when murine melanoma cells (Figures 2F and
G), as well as normal human melanocytes (data not
hown), were treated with melanogenin in combination
ith the pigmentation promoters IBMX, α-MSH, and
he MAPK inhibitor PD98059.
dentification of Prohibitin as a Melanogenin
rotein Target
rotein target isolation required covalent attachment of
elanogenin via its internal linker to an agarose beadaffinity matrix (ethanolamine-coated to prevent non-
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479specific binding). In preparation for affinity matrix syn-
thesis, bulky benzoyl and acetyl groups were substi-
tuted at the future site of agarose bead attachment.
These functionalized melanogenin molecules retained
activity, suggesting that attachment of the affinity ma-
trix would not affect biological function (Figure 3A).
Equivalent functionalization of E28 did not alter its lack
of activity (data not shown). The synthesis of melano-
genin and E28 affinity matrices was accomplished (Fig-
ure 3B), and identification of melanogenin binding pro-
teins was performed by incubation of matrix bound
melanogenin with total melanocyte protein extract and
fractionating retained targets using SDS-PAGE. In mul-
tiple experiments, a 32 kDa band was identified that
bound specifically to the melanogenin matrix but not to
the ethanolamine-coated agarose beads alone nor to
the E28 matrix (Figure 3C). This species was cut from
the gel, trypsin-digested, and sequenced using mass
spectrometry. An NCBI conserved domain search of the
peptide fragments yielded 98.9% homology with pro-
hibitin (Figure 3D).
To verify the specificity of melanogenin-prohibitin
binding, we incubated melanocyte protein extract with
either melanogenin matrix or ethanolamine-coated agar-
ose beads alone. Samples were briefly preincubated
with free melanogenin, inactive E28, or vehicle before
adding the melanogenin affinity matrix. Following pro-
tein resolution and immunoblotting for prohibitin, we
found that free melanogenin, but not inactive E28 or
DMSO vehicle, effectively competed for the binding of
prohibitin to the melanogenin matrix (Figure 3E). We
therefore concluded that melanogenin binds prohibitin
specifically.
Identification of a Functional Role for Prohibitin
in Melanin Induction
Wild-type melanocytes were transfected with negative
control (no mammalian homology) siRNA, two distinct
prohibitin siRNA sequences, or Lamin A/C (irrelevant
mammalian) siRNA. Adequate and specific prohibitin
gene silencing was achieved and demonstrated through
immunoblotting (Figure 4A). After 24 hr, transfected
cells were treated with DMSO vehicle, 5 M melano-
genin, 5 M E28, or 100 M IBMX and harvested after
48 hr for melanin assay. Cells transfected with prohibi-
tin siRNA, but not negative control or Lamin A/C siRNA,
displayed a significantly attenuated response to mela-
nogenin (Figure 4B). Those cells transfected with either
prohibitin siRNA sequence also displayed a modest at-
tenuation in their response to the known promoter
IBMX (Figure 4B).
Discussion
In this study we employed the use of a chemical ge-
netic approach to dissect the mammalian pigmentation
pathway. Using a tagged triazine library and affinity pu-
rification methods, we have identified prohibitin as a
target of melanogenin. In addition, through the use of
siRNA technology, we report what we believe to be a
novel role for prohibitin in melanin induction.
The melan-A cell line utilized in the cell-based
screening assay is a spontaneously immortalized, non-
tumorigenic line of melanocytes obtained from theskins of C57Bl/6J mice [11]. Melan-A cells provide a
number of attractive characteristics for the chemical
genetics approach we employed. They divide rapidly,
but maintain a highly differentiated phenotype with ap-
parently normal and well-studied melanosomal struc-
ture and expression of pigmentation-related proteins.
Our chemical library provided several advantages, in-
cluding the rapid and inexpensive achievement of
chemical diversity as well as offering the potential for a
high biological “hit” rate. The triazine scaffold has
3-fold symmetry, enabling substantial flexibility in diver-
sity-generating modifications. Due to its ease of manip-
ulation and the low price of the starting material, tri-
azine has elicited considerable interest as a scaffold in
combinatorial libraries, resulting in the publication of
several triazine-based libraries [10, 16–18]. It is known
that a high percentage of proteins interact with purines
and pyrimidines (e.g., adenosine, ATP, GTP, cyclic AMP,
etc.); the structural similarity between triazines and pu-
rines and pyrimidines is hypothesized to increase the
chance that library molecules will interact with target
proteins.
Despite its power and elegance, the chemical genetic
approach is limited by certain methodological difficul-
ties. Traditionally, in order to add a linker to an active
molecule without activity loss, a thorough structure-
activity relationship study of the chemical is required to
find the proper site for linker addition. This procedure is
cumbersome and sometimes impossible. To avoid this
problem, we designed our library of small molecules
to carry an internal tag from the outset [10, 17]. Thus,
compounds found to be active in screening could be
directly connected via their internal tags to create affin-
ity resins without the need for extensive SAR studies in
order to find a linker site that does not disrupt activity.
Several experiments were performed to investigate
whether melanogenin could act in combination with
other known pigmentation promoters. Our results dem-
onstrated a remarkable additive effect when melano-
genin was added in combination with the known stimu-
lators IBMX, α-MSH, and the MAPK inhibitor PD98059
to both melanocytes (data not shown) and melanoma
cells (Figures 2F and 2G). These findings suggest a
convergence of the pathways modulated by melano-
genin with those affected by the other agents.
We cannot as yet distinguish between the possibility
that melanogenin’s effects are specific to pigmentation
pathways in melanocytes and that of it having a role in
differentiation. Indeed, pigmentation and differentiation
are often viewed as being closely linked, as demon-
strated by the role of micropthalmia-associated tran-
scription factor (MITF) in the regulation of melanogen-
esis [19]. Whereas no gross effects of melanogenin on
cell growth were observed, treatment results in a strik-
ing increase in dendricity in both melanocytes and mel-
anoma cells. This phenotypic change suggests the dis-
tinct possibility that melanogenin’s effects are carried
out via modulation of melanocyte differentiation.
Further studies employing affinity purification meth-
ods identified prohibitin as a melanogenin binding
target. Prohibitin is a mitochondrial protein that exists
in a dimeric complex with Bap37 on the inner mitochon-
drial membrane [20, 21], although a nuclear localization
has been observed by some authors [22]. Immunofluo-
rescence microscopy demonstrated mitochondrial pro-
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480Figure 2. Melanogenin Induces Melanin Formation, Tyrosinase Protein Levels, and Tyrosinase Activity in a Dose-Dependent Fashion in Melano-
cytes and Melanoma Cells and Acts in Combination with Known Promoters
(A) Phase-contrast images of wild-type cultured murine melanocytes treated with 0.1% dimethylsulfoxide (DMSO) vehicle, positive-control
100 M isobutylmethylxanthine (IBMX), 10 M melanogenin, or 10 M E28 (scale = 250 m). Note that the melanogenin EC50 is 2.5 M and
that significant cytotoxicity does not occur at concentrations below 20 M.
(B) The number of pigmented cell bodies was quantified from each phase photograph using Scion Image and Adobe Photoshop.
(C) Melanin assay of melanocytes treated with melanogenin and the inactive molecule E28. Data marked with an asterisk represent statistically
significant increases in pigmentation above vehicle-treated melanocytes using the Student’s t test (p < 0.01). Error bars represent ±1 SD.
Note that data adjusted for total protein yielded identical results.
(D) Antityrosinase and anti-Trp-1 Western blots from melanocytes treated with melanogenin, IBMX, DMSO vehicle, and E28. Tyrosinase-
related protein 1 (Trp-1) is a melanogenic protein unaffected by melanogenin treatment. Lysosomal-associated membrane protein 1 (Lamp-1) is a
marker of late endosomes and serves as a loading control. Lamp-1 is represented twice, as the Tyr and Trp-1 results are the product of
distinct SDS-PAGE gels. Data shown in (A)–(D) are from the same representative experiment.
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481To determine whether prohibitin has a functional rolepression [25–29], have been proposed. These functions
(E) Tyrosinase enzyme activity assay on melanocyte extracts in which cells were previously treated with IBMX, melanogenin, IBMX, and
melanogenin in combination. Untreated melanocytes and melan-C melanocytes (melanocytes containing mutant, inactive tyrosinase) [15]
served as controls in this experiment. The asterisk indicates a statistically significant increase in enzyme activity above untreated melanocytes
using Student’s t test (p < 0.05). Error bars represent ±1 SD. Note that data adjusted for total protein yielded identical results. Tyrosinase
activity was also statistically significantly increased in those cells treated with melanogenin in combination with IBMX above either compound
tested alone (p < 0.05).
(F) Phase photographs of B16F10 murine melanoma cells treated with melanogenin in combination with known promoters α-MSH, IBMX, and
the MAPK inhibitor PD98059, illustrating a dramatic increases in melanogenesis and dendricity.
(G) Melanin assay of B16F10 melanoma cells reveals an additive effect in response to treatment with melanogenin in combination with the
known promoters IBMX, α-MSH, and PD98059. All chemicals (including combinations) were tested at noncytotoxic concentrations as mea-
sured by cell viability assay (data not shown). Data adjusted for total protein yielded identical results. All combination treatments represent a
statistically significant increase in melanogenesis above untreated melanoma cells using Student’s t test (p < 0.01). The increase in melaninFigure 3. Immobilized Melanogenin Binds the Mitochondrial Protein Prohibitin Specifically
(A) Melanogenin substituted with the benzoyl (Bz) functional group at the future site of affinity matrix attachment retains its in vitro activity.
E28 with the identical substitution remained inactive (data not shown). Error bars represent ±1 SD.
(B) Chemical structures of the melanogenin and E28 affinity labels. Melanogenin and E28 are immobilized on activated agarose beads (Affi-
gel 10) coated with ethanolamine to block nonspecific binding sites.
(C) Silver-stained 5%–15% gradient SDS-PAGE gel illustrating melanogenin-specific protein binding. “A” denotes the unconjugated ethanol-
amine-treated agarose bead matrix. “Melanogenin-A” and “E28-A” represent the corresponding triazine library members linked to agarose
bead affinity matrices.
(D) Amino acid sequence results of a 32 kDa melanogenin-specific protein cut from the SDS-PAGE gel. The protein was digested with trypsin,
yielding amino acid fragments that were subsequently identified using mass spectrometry. These fragments are illustrated in red and overlap
with the murine prohibitin sequence, yielding 98.9% homology by NCBI conserved domain search.
(E) Antiprohibitin Western blot from melanocyte extract incubated with melanogenin-A or agarose beads alone. Melanogenin-prohibitin bind-
ing was substantially diminished upon 10 min preincubation with free melanogenin but not with inactive E28 or DMSO vehicle.
(F) Immunofluorescence studies illustrating mitochondrial prohibitin localization in melan-A melanocytes.hibitin localization in melanocytes (Figure 3F). Treat-
ment with melanogenin did not alter prohibitin cellular
location (data not shown). Functional roles for prohibi-
tin in diverse biological processes, such as aging [23],
senescence [24, 25], development [25], and tumor sup-production as a result of the melanogenin/promoter combinations was al
tested alone (p < 0.05). These results are identical in melan-A mouse melamay be explained by data that suggest that prohibitin
may function chiefly as a molecular chaperone [30]. In-
terestingly, it has recently been shown, using a proteo-
mic approach, that prohibitin is highly expressed in mu-
rine epidermis [31].so statistically significant when compared to any of the promoters
nocytes. Error bars represent ±1 SD.
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482Figure 4. Prohibitin Gene Silencing Effectively Attenuates the Cellular Response to Melanogenin
(A) Antiprohibitin Western blot from melanocytes transfected with two distinct prohibitin siRNA sequences (Phb1 and Phb2), negative control
siRNA, or Lamin A/C siRNA followed by 0.05% DMSO, 5 M melanogenin, 5 M E28 or 100 M IBMX treatment. Lamp-1 serves as a
loading control.
(B) Melanin assay of melanocytes transfected with two distinct prohibitin siRNA sequences (Phb1 and Phb2), negative control siRNA, or
Lamin A/C siRNA followed by 0.05% DMSO, 5 M melanogenin, 5 M E28, or 100 M IBMX treatment. Note that all data in this figure that
were adjusted for total protein yielded identical results. All data are the product of the same representative experiment.pin the induction of pigmentation, siRNA technology was
autilized to selectively silence prohibitin gene expression
(Figure 4A). We demonstrated a significant attenuation
Bin the cellular response to melanogenin following spe-
B
cific prohibitin gene silencing (Figure 4B). These data e
suggest that prohibitin expression is required for the 1
bstimulation of pigmentation by melanogenin, and thus
5implicate prohibitin in inducible, rather than endoge-
cnous, melanogenesis. The intermediary proteins medi-
ating this cellular response, as well as the nature of the
Cinteraction between melanogenin and prohibitin, have
M
yet to be further characterized. E
r
nSignificance l
(
We have demonstrated the use of a chemical genetic w
Tapproach to the dissection of melanogenesis and
nidentified what we believe to be a novel class of pig-
ment-promoting molecules. We have characterized
pthe small-molecule probe, melanogenin, identified a c
specific intracellular target as the mitochondrial pro- 1
tein prohibitin, and discovered a functional role for c
cthis protein in melanin induction. These results may
wultimately aid in the pursuit of therapies for pigmen-
mtary disorders by providing a potential target for ratio-
a
nal drug design. A
u
sExperimental Procedures
Chemical Synthesis and Library Design M
CThe synthetic method for the tagged triazine library has been re-
ported previously [10]. Briefly, a solid-phase method was used to w
rconstruct a tagged triazine library, where three building blocks
were assembled orthogonally yielding 1170 highly pure com- counds. Each compound contained a triethyleneglycol (TG) linker
t one of the triazine scaffold sites.
uffers
uffers used were an extraction buffer (50 mM Tris [pH 7.5]; 2 mM
thylenediamine tetraacetic acid [EDTA] [pH 7.8]; 150 mM NaCl;
% Triton X-100) containing protease inhibitor cocktail and a bead
uffer (50 mM Tris [pH 7.4]; 250 mM NaCl; 5 mM EDTA; 5 mM EGTA;
mM NaF; 0.1% Nonidet P-40) containing protease inhibitor
ocktail.
ell Culture and Screening Method
elan-A melanocytes [11] were maintained in Dulbecco’s modified
agle’s medium (DMEM) supplemented with 10% fetal bovine se-
um (FBS), 2 mM L-glutamine, 1 mM sodium pyruvate, 1% MEM
onessential amino acids 100×, 100,000 U liter−1 penicillin, 100 mg
iter−1 streptomycin, and 200 ηM tetradecanoyl phorbol acetate
TPA-Sigma) at 37°C and 8% CO2. B16F10 murine melanoma cells
ere maintained and cultured as above without the addition of
PA. Melan-C melanocytes [12] were maintained as melan-A mela-
ocytes with the addition of 100 ηM β-mercaptoethanol.
Screening in melan-A melanocytes was performed in 24-well
late format with a seeding density of 50,000 cells/cm2. Library
ompounds stored in 96-well plates at a stock concentration of
0 mM in dimethylsulfoxide (DMSO) were tested in vitro at a final
oncentration of 5M. For each experiment, a DMSO (Sigma) vehi-
le control and an isobutylmethylxanthine (Sigma) positive control
ere utilized. Cells were cultured for 72 hr followed by quantitative
elanin assay. Cell photographs were obtained after 72 hr using
n Axiovert 10 (Carl Zeiss) phase microscope and processed using
dobe Photoshop 6.0 (Adobe systems). Cell viability was assessed
sing the CellTiter 96 aqueous nonradioactive cell proliferation as-
ay (Promega).
elanin Assays
ells were rinsed with phosphate-buffered saline (PBS) and lysed
ith extraction buffer at 4°C. Cell extracts were then spun at 14,000
pm for 5 min at 4°C. Supernatants were removed and protein con-
entration was determined using the Bradford method. The remain-
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ether (1:1) and dissolving it in 250 l of 2 N NaOH/20% DMSO at
60°C. A 200 l aliquot of the resulting solution was measured for
absorbance at 490 nm. α-melanocyte-stimulating hormone (MSH;
Sigma), PD98059 (Biomol), and IBMX (Sigma) were utilized with
melanogenin for synergy experiments.
Western Blotting
Following protein concentration determination using the Bradford
method, 10 g of total protein extract was combined with 2×
Laemmli sample buffer containing β-mercaptoethanol. Samples
were heat denatured and resolved on 10% SDS-PAGE gels. Follow-
ing protein transfer to PVDF membrane, samples were probed with
primary antibodies to tyrosinase (rabbit polyclonal α-PEP-7), Trp-1
(rabbit polyclonal α-PEP-1), prohibitin (mouse monoclonal-Lab Vi-
sion/Neomarkers), and Lamp-1 (rat polyclonal 1D4B-Develop-
mental Studies Hybridoma Bank, Iowa City, IA). The α-PEP-7 and
α-PEP-1 antibodies were gifts from Dr. Vincent Hearing, National
Cancer Institute. Following wash cycles, membranes were probed
with secondary donkey anti-rabbit IgG (Amersham), goat anti-
mouse IgG (Accurate Chemical & Scientific Corporation), or goat
anti-rat IgG (Accurate Chemical & Scientific Corporation) antibod-
ies. Membranes were washed and films were generated using ECL
detection reagent (NEN Life Science Products) and X-OMAT pro-
cessing.
Tyrosinase Assays
Tyrosinase activity assays were performed on melanocyte cell ex-
tracts as previously described [13, 14]. Briefly, aliquots of cellular
extract normalized for total protein were incubated with 1.5 Ci 3H
tyrosine and 1.5 mg ml−1 DOPA for 1 hr at 37°C in 0.1 M NaPO4
and 1% (v/v) Triton X-100. The reaction was terminated through the
addition of 10% (w/v) activated charcoal in 0.1 M citric acid and
filtered through a cationic exchange resin column. The 3H2O reac-
tion product was measured using a Beckman LS 6000SC scintilla-
tion counter (Beckman Instruments).
Affinity Chromatography
Before use, 25 l of packed affinity resin (4 mol/ml stock concen-
tration stored as a 50% v/v slurry in 2% NaN3 at 4°C) was washed
three times with 1 ml of bead buffer. The beads were resuspended
in 400 l of this buffer and an equal volume, containing 500 g of
total protein extract, was added to each sample. The tubes were
subsequently rotated at 37°C for 30 min. After removing the super-
natant by centrifugation at 12,000 rpm, the beads were washed
extensively with bead buffer. The bound proteins were subse-
quently recovered with 30 l of 2× Laemmli sample buffer, contain-
ing β-mercaptoethanol, followed by denaturation and resolution
using SDS-PAGE.
For competition experiments, free melanogenin, E28, or DMSO
was first added in 5-fold excess to each 500 g protein sample
and incubated for 10 min rotating at 37°C. Following this preincu-
bation, 25 l of packed melanogenin affinity resin or the ethanol-
amine-coated agarose beads alone were added to the samples and
allowed to incubate for an additional 20 min. Proteins were subse-
quently recovered and resolved, as detailed above, followed by
transfer to PVDF membrane and immunoblotting for prohibitin.
Electrophoresis and Protein Identification
Following denaturation, proteins were resolved on a 5%–15% gra-
dient SDS-PAGE gel. Visualization of bound proteins was accom-
plished using the PlusOne silver staining kit (Amersham Biosci-
ences). The band of interest was excised from the gel under sterile
conditions, destained, and digested with trypsin. Amino acid se-
quencing was performed using a Micromass QTOF mass spec-
trometer. These data were used to search the NCBI nonredundant
protein database using the Mascot search engine.
Immunofluorescence
Melan-A melanocytes were prepared as described previously [15].
MitoTracker (Molecular Probes) was added to cells in DMEM media
at a final concentration of 200 ηM and incubated for 20 min at 37°C.
The media were removed and the cells were washed with PBS.Following removal of PBS, the cells were fixed with cold methanol
for 5 min at −20°C. The cells were washed with PBS followed by
permeabilization in 0.5% saponin/PBS for 15 min at room temper-
ature. Following a PBS rinse the cells were incubated with rabbit
polyclonal anti-prohibitin antibody (Lab Vision/Neomarkers) at a
1:30 dilution for 1 hr at 37°C. The cells were then washed with
PBS and incubated with Alexa 488 conjugated anti-rabbit antibody
(Molecular Probes) at a 1:200 dilution for 1 hr at 37°C. Slides were
subsequently treated with ProLong Antifade (Molecular Probes)
and analyzed using a confocal microscope (LSM510; Carl Zeiss).
Data were processed using Adobe Photoshop 6.0 (Adobe
Systems).
siRNA Studies
Custom prohibitin siRNA was purchased from Ambion, Inc. Nega-
tive control (no mammalian homology) siRNA, Lamin A/C (irrelevant
mammalian) siRNA, and RNAiFect transfection reagent were
purchased from Qiagen. At 24 hr prior to transfection, melanocytes
were seeded in triplicate in 24-well plate format at a density of
50,000 cells/well and incubated in media containing 10% serum,
antibiotics, and growth factors. After 24 hr, 1.5 g of sample siRNA
was diluted in low-serum media containing antibiotics (Opti-MEM
I-Gibco) to a final volume of 100 l and vortexed. Complex forma-
tion was achieved by adding 9 l of RNAiFect transfection reagent
to the diluted siRNA. Complexes were mixed, incubated, and
added drop-wise to cells contained in 300 l of low-serum media
with antibiotics and TPA. Cells were incubated under normal
growth conditions for 3 hr, at which point the low-serum media
containing siRNA complexes was removed and replaced with me-
dia containing 10% serum, antibiotics, and growth factors. Gene
silencing was allowed to proceed for 24 hr before the addition of 5
M melanogenin or 0.05% DMSO vehicle to wells containing nega-
tive control, prohibitin, or Lamin A/C siRNA. Samples were har-
vested following a 48 hr incubation and subjected to quantitative
melanin assay. Gene silencing was verified by immunoblotting at
the time of harvest. All experimental data are derived from tripli-
cate samples.
Statistical Analysis
Data analyses were performed using the two-tailed Student’s t test.
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